The Lynx Group

Questions About Treating Patients Using a CDK4/6 Inhibitor

Videos — January 10, 2018

Featuring:

Dr Matthew Goetz addresses common questions that arise when patients with HER-positive metastatic breast cancer have progressed on a CDK4/6 inhibitor plus an aromatase inhibitor.

Related Articles

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: